Investor's Business Daily on MSN48m
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected HitchHims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback